## Contextual Query Report: AC-gliosis-like 1

**Query:**
> The following is a list of genes enriched in Malignant cells from a (human) patient with glioblastoma  annotated as Astrocyte-gliosis-like.  What might this list say about the state, properties and interactions of this cell type?  Do not limit your answers to the cancer literature,  include normal cell-cell interactions, development and cross-cutting metabolic states.  Gene list: ['POSTN', 'JPH1', 'EYA4', 'RTN1', 'LAMA2', 'AC092957.1', 'TNC', 'IGFBP7', 'COL23A1', 'NAMPT']

**Response:**
<think>
We are given a list of genes that are enriched in malignant cells from a glioblastoma patient, and these cells are annotated as "Astrocyte-gliosis-like". Our task is to interpret what this gene list might say about the state, properties, and interactions of this cell type. We must consider normal cell biology, development, metabolic states, and interactions beyond just cancer literature.

The genes are: ['POSTN', 'JPH1', 'EYA4', 'RTN1', 'LAMA2', 'AC092957.1', 'TNC', 'IGFBP7', 'COL23A1', 'NAMPT']

We have search results from various sources that can help us understand the functions of these genes. We will go through each gene and relate it to astrocyte function, reactive astrogliosis, and the context of glioblastoma.

1. **POSTN (Periostin)**: 
   - According to [7], POSTN is a matricellular protein that plays roles in survival, migration, and regeneration. It is expressed in the CNS during development and re-expressed after injury. It promotes neural stem cell (NSC) proliferation and differentiation. In the context of astrocytes, it might be involved in reactive astrogliosis and tissue remodeling. In glioblastoma, this could indicate a role in promoting tumor cell proliferation and invasion.

2. **JPH1 (Junctophilin 1)**:
   - From [12], junctophilins are involved in forming junctions between the endoplasmic reticulum (ER) and the plasma membrane, which are critical for calcium signaling. JPH1 is expressed in neural tissue and helps in stabilizing calcium microdomains. In astrocytes, calcium signaling is vital for their function. In the context of glioblastoma, dysregulation of calcium signaling might contribute to tumor cell survival and migration.

3. **EYA4 (Eyes Absent Homolog 4)**:
   - [14] indicates that EYA4 is a transcriptional coactivator involved in developmental processes, including in the nervous system. Mutations in EYA4 are associated with hearing loss, but its role in astrocytes is less clear. It might be involved in developmental pathways that are reactivated in cancer. In glioblastoma, it could contribute to aberrant transcriptional programs.

4. **RTN1 (Reticulon 1)**:
   - [2] and [13] discuss reticulons (RTNs) as ER-shaping proteins. RTN1-C interacts with MANF (mesencephalic astrocyte-derived neurotrophic factor), which is important for neuronal survival and ER stress responses [13]. In astrocytes, RTN1 might be involved in ER remodeling during stress. In glioblastoma, ER stress responses are often dysregulated, promoting survival under stress.

5. **LAMA2 (Laminin Subunit Alpha 2)**:
   - [18] describes LAMA2 as a component of laminins in the extracellular matrix (ECM), particularly in the basement membrane. It is crucial for blood-brain barrier (BBB) integrity and is produced by astrocytes. In glioblastoma, LAMA2 might contribute to the abnormal ECM that supports tumor invasion and angiogenesis.

6. **AC092957.1**:
   - This appears to be a long non-coding RNA (lncRNA). From [3] and [6], we see that AC092957.1 is mentioned in the context of genomic instability in low-grade gliomas (LGGs). LncRNAs can regulate gene expression epigenetically. In astrocytes, it might be involved in the regulation of reactive responses. In cancer, lncRNAs often contribute to oncogenic pathways.

7. **TNC (Tenascin C)**:
   - [11] and [17] highlight TNC as an ECM glycoprotein produced by reactive astrocytes. It is involved in development and injury responses, acting as a modulator of cell adhesion and migration. In glioblastoma, TNC is often upregulated and associated with poor prognosis, promoting invasion and resistance to therapy.

8. **IGFBP7 (Insulin-like Growth Factor Binding Protein 7)**:
   - [10] shows that IGFBP7 is downregulated in some cancers (like hepatocellular carcinoma) but may have context-dependent roles. It can act as a tumor suppressor by inducing senescence. In astrocytes, IGFBP7 might regulate responses to growth factors. In glioblastoma, it could be involved in autocrine/paracrine signaling.

9. **COL23A1 (Collagen Type XXIII Alpha 1 Chain)**:
   - [9] indicates that COL23A1 is a transmembrane collagen expressed by neurons in specific brain regions (like the accessory olfactory bulb). Its role in astrocytes is not well-established, but it might be involved in cell-matrix interactions. In cancer, collagens can influence tumor progression.

10. **NAMPT (Nicotinamide Phosphoribosyltransferase)**:
    - [15] and [16] discuss NAMPT as the rate-limiting enzyme in the NAD+ salvage pathway. Astrocytes use NAD+ for energy and immune responses. In [15], NAMPT is crucial for proinflammatory astrocyte activation. In glioblastoma, increased NAD+ metabolism might support tumor growth and resistance to stress.

Now, integrating these genes into a cohesive picture of the "Astrocyte-gliosis-like" malignant cells:

- **Reactive Astrocyte Signature**: The presence of TNC, POSTN, and LAMA2 suggests an extracellular matrix remodeling phenotype, typical of reactive astrocytes. This is further supported by COL23A1 (a collagen) and IGFBP7 (an ECM-associated protein). These genes indicate that the cells are producing an abnormal ECM that may facilitate invasion and angiogenesis.

- **Calcium and ER Dynamics**: JPH1 and RTN1 point towards dysregulated calcium signaling and ER morphology. In reactive astrocytes, calcium waves are important for intercellular communication. In cancer, altered calcium signaling can promote proliferation and migration.

- **Metabolic Reprogramming**: NAMPT is key in NAD+ metabolism. Reactive astrocytes often undergo metabolic shifts (e.g., towards glycolysis), and NAD+ is crucial for energy production and inflammation. In glioblastoma, this might support the high metabolic demands of tumor cells and modulate the tumor microenvironment.

- **Developmental Pathways**: EYA4 is a transcriptional coactivator involved in development. Its re-expression in cancer might reactivate developmental programs that drive stem-like properties (e.g., in neural stem cells). This is consistent with the glioblastoma stem cell hypothesis.

- **Non-coding RNA**: AC092957.1, as a lncRNA, might regulate these pathways epigenetically. LncRNAs can control chromatin states and gene expression, potentially maintaining the tumor-promoting state.

- **Cross-cutting Metabolic States**: The NAD+ pathway (via NAMPT) links to cellular energetics and redox balance. Reactive astrocytes in glioblastoma might use NAD+ to fuel proinflammatory responses and resist oxidative stress.

- **Cell-Cell Interactions**: 
  - Astrocytes normally interact with neurons, endothelial cells, and microglia. 
  - TNC and POSTN can modulate interactions with the ECM and other cells (e.g., immune cells). 
  - LAMA2 is critical for BBB integrity; its dysregulation might contribute to BBB breakdown in glioblastoma, facilitating immune cell infiltration and tumor spread.
  - IGFBP7 might mediate interactions with growth factors (e.g., IGFs) in the microenvironment.

- **Gliosis in Cancer**: Reactive astrogliosis is a response to injury, but in glioblastoma, this response is co-opted to support tumor growth. The gene list suggests a chronic, maladaptive gliosis that promotes tumor progression via ECM remodeling, altered metabolism, and dysregulated signaling.

In conclusion, the gene signature indicates that the "Astrocyte-gliosis-like" malignant cells in glioblastoma exhibit:
- A reactive ECM-remodeling phenotype (TNC, POSTN, LAMA2, COL23A1, IGFBP7)
- Altered intracellular signaling (JPH1, RTN1, EYA4)
- Metabolic adaptation with a focus on NAD+ metabolism (NAMPT)
- Epigenetic regulation (AC092957.1)

These properties likely contribute to tumor invasion, immune evasion, and resistance to therapy. The state resembles a chronic, non-resolving gliotic response that supports tumor growth.

We will now structure the report accordingly.
</think>
### Enriched Gene Signature in Glioblastoma Astrocyte-Gliosis-Like Malignant Cells: Implications for Cellular State, Interactions, and Metabolic Reprogramming  

The gene signature identified in malignant astrocyte-gliosis-like cells from glioblastoma patients—comprising **POSTN**, **JPH1**, **EYA4**, **RTN1**, **LAMA2**, **AC092957.1**, **TNC**, **IGFBP7**, **COL23A1**, and **NAMPT**—reveals a multifaceted cellular phenotype rooted in extracellular matrix (ECM) remodeling, metabolic dysregulation, and aberrant developmental signaling. This profile mirrors conserved astrocytic responses to injury, metabolic stress, and developmental pathways, now co-opted in malignancy. Below, we dissect the implications across cellular states, interactions, and metabolic adaptations, integrating insights from neurodevelopment, homeostasis, and disease contexts.  

---

### ECM Remodeling and Structural Dysregulation  
Astrocyte-gliosis-like cells exhibit pronounced ECM dysregulation, driven by:  
- **Tenascin-C (TNC)**: A key ECM glycoprotein re-expressed in reactive astrocytes under pathological conditions. TNC restricts astrogliosis and modulates astrocyte-microglial crosstalk, but in glioblastoma, its overexpression may facilitate invasive tumor growth by disrupting normal tissue architecture[11][17]. TNC's interaction with fibronectin domains and L-type Ca²⁺ channels further implicates it in calcium signaling dysregulation, a hallmark of glioma progression[11][17].  
- **Periostin (POSTN)**: This matricellular protein promotes neural stem cell proliferation and differentiation. In glioblastoma, POSTN likely drives tumor expansion by enhancing cell adhesion, ECM deposition, and activation of integrin-mediated pathways[7]. Its homology to fasciclin I suggests roles in neurite outgrowth, potentially enabling network integration of malignant cells[7].  
- **Laminin-α2 (LAMA2)**: Critical for blood-brain barrier (BBB) integrity, LAMA2 anchors astrocytes to endothelial cells via dystroglycan and α7β1 integrins. Loss of LAMA2 in neurovascular units correlates with BBB dysfunction, pericyte detachment, and reactive gliosis—features exacerbated in glioblastoma to promote angiogenesis and immune infiltration[18][8].  
- **Collagen XXII Alpha 1 (COL23A1)**: A transmembrane collagen enriched in neuronal layers (e.g., mitral/tufted cells of the olfactory bulb). Its presence in glioblastoma implies aberrant re-activation of developmental collagen pathways, potentially altering cell-ECM signaling and tissue stiffness[9].  

---

### Intracellular Signaling and Organelle Dynamics  
Dysregulation of endoplasmic reticulum (ER) and calcium homeostasis underpins malignant transformation:  
- **Reticulon-1 (RTN1)**: Shapes ER tubules and modulates ER stress responses. RTN1-C interacts with mesencephalic astrocyte-derived neurotrophic factor (MANF), linking ER integrity to neuroprotection. In glioblastoma, RTN1 may drive adaptive ER expansion to support protein synthesis and stress survival[2][13].  
- **Junctophilin-1 (JPH1)**: Tethers ER to the plasma membrane to regulate Ca²⁺ microdomains. JPH1 stabilizes Cav1-RyR2-KCa3.1 complexes in neurons; its dysregulation in astrocytes could disrupt Ca²⁺-dependent gliotransmission, promoting excitotoxicity and tumor invasion[12].  

---

### Metabolic Reprogramming  
NAD⁺ salvage pathway activation fuels proinflammatory and survival pathways:  
- **Nicotinamide Phosphoribosyltransferase (NAMPT)**: The rate-limiting enzyme in NAD⁺ biosynthesis. NAMPT upregulation in reactive astrocytes drives glycolysis and oxidative phosphorylation, supporting inflammatory gene transcription via CD38/NFAT signaling. In glioblastoma, this sustains tumor energy demands and evasion of oxidative stress[15][16].  
- **Insulin-like Growth Factor Binding Protein 7 (IGFBP7)**: A senescence inducer downregulated in cancers. IGFBP7 binds activin A and heparan sulfate, modulating TGF-β signaling. Its loss in glioblastoma may disable tumor-suppressive ECM cues, while its re-expression could impair angiogenesis[10].  

---

### Developmental and Epigenetic Reawakening  
Genes typifying neural development are aberrantly activated:  
- **Eyes Absent Homolog 4 (EYA4)**: A transcriptional co-activator in sensory development. EYA4 mutations cause hearing loss via disrupted neurodevelopment. In glioblastoma, EYA4 may reactivate stemness programs, fostering dedifferentiation[14].  
- **Long Non-Coding RNA AC092957.1**: Associated with genomic instability in gliomas. lncRNAs like AC092957.1 can silence tumor suppressors or amplify oncogenic pathways, contributing to the "astrocyte-gliosis" epigenetic landscape[3][6].  

---

### Cross-Tissue Interactions  
Gliosis-like malignant cells engage in pathological crosstalk:  
- **Neuron-Astrocyte Axis**: Calcium dysregulation (JPH1) and ECM disruption (TNC, POSTN) impair synaptic stability. TNC-mediated phagocytic pruning of synapses may be hijacked to eliminate neuronal inhibition of tumor growth[1][17].  
- **Microglia and Immune Cells**: TNC and IGFBP7 modulate cytokine release (e.g., via NF-κB), recruiting microglia. NAD⁺-driven astrocyte inflammation (NAMPT) further polarizes immune cells toward tumor tolerance[11][15][17].  
- **Vascular Niche**: LAMA2 loss and TNC overexpression degrade BBB tight junctions, facilitating angiogenesis. Hypoxia-inducible factors (e.g., HIF-1α) may synergize with NAMPT to fuel metabolic adaptation in perivascular niches[8][15][18].  

---

### Metabolic State Integration  
Astrocyte-gliosis-like cells exhibit a "Warburg-like" metabolic shift:  
1. **Glycolytic Flux**: NAMPT-driven NAD⁺ recycling enhances glycolysis, supplying ATP for phagocytic and inflammatory activity—mirroring reactive astrocytes in neurodegeneration[1][15].  
2. **Lipid and Protein Stress**: RTN1 and JPH1 alter ER morphology, disrupting lipid metabolism and protein folding. This may activate unfolded protein responses, increasing chaperone expression (e.g., HSP90)[4][12].  
3. **Redox Imbalance**: NAD⁺ depletion amplifies oxidative stress. Paradoxically, NAMPT upregulation may counter this by fueling antioxidant pathways, illustrating a metabolic trade-off in malignancy[16].  

---

### Conclusion  
The enriched gene signature in astrocyte-gliosis-like glioblastoma cells depicts a maladaptive state where developmental, metabolic, and structural programs converge. Key features include:  
- **ECM Dysplasia**: TNC, POSTN, and LAMA2 create a tumor-permissive matrix.  
- **Metabolic Plasticity**: NAMPT sustains inflammation and stress resilience.  
- **Developmental Reversion**: EYA4 and AC092957.1 reawaken neural stem cell-like traits.  
- **Network Dysfunction**: Altered ER/calcium dynamics (RTN1, JPH1) and immune crosstalk drive progression.  

This phenotype mirrors conserved astrocyte responses to injury but is locked in a self-amplifying loop of invasion and metabolic opportunism. Targeting NAMPT or TNC may disrupt this equilibrium, offering therapeutic entry points[11][15][17]. Future work should explore single-cell spatial transcriptomics to deconvolute heterogeneous glioblastoma microenvironments.



## References

- [1] https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1393253/full
- [2] https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00048/full
- [3] https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.758596/text
- [4] https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2023.1173200/pdf
- [5] https://journals.plos.org/plosone/article/file?type=supplementary&id=10.1371%2Fjournal.pone.0032917.s003
- [6] https://www.frontiersin.org/api/v4/articles/937531/file/Table_2.xlsx/937531_supplementary-materials_tables_2_xlsx/2
- [7] https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0123585
- [8] https://pubmed.ncbi.nlm.nih.gov/36098369/
- [9] https://www.frontiersin.org/journals/integrative-neuroscience/articles/10.3389/fnint.2017.00020/full
- [10] https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00727/full
- [11] https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2012.00120/full
- [12] https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.635518/full
- [13] https://pubmed.ncbi.nlm.nih.gov/25543119/
- [14] https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0126602
- [15] https://pubmed.ncbi.nlm.nih.gov/35994674/
- [16] https://pubmed.ncbi.nlm.nih.gov/27002158/
- [17] https://pubmed.ncbi.nlm.nih.gov/35430380/
- [18] https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2020.00118/full
- [19] https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.607587/full